Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

Thermo Fisher Scientific выглядит как качественный, но не дешёвый бизнес: по прибыли и марже компания сильна, однако рынок уже закладывает высокий уровень качества в цену. P/E 26.33, P/S 3.99, P/B 3.53 и P/FCF 29.58 находятся заметно выше медианы отрасли, что ограничивает потенциал переоценки и делает акцию чувствительной к любому замедлению роста. При этом мультипликаторы в последние периоды в целом снижались с более высоких уровней, что говорит о некотором улучшении оценки, но не снимает премию к сектору. Рентабельность выглядит устойчивой: net profit margin около 15%, operating margin 17.39%, ROA 6.40% и ROE 13.24% подтверждают способность генерировать прибыль на базе крупного бизнеса. Слабее смотрится gross margin 41.07%, который ниже отраслевой медианы, а ROE и ROI также отстают от медианы, что указывает на неидеальную отдачу на капитал. Ликвидность вызывает осторожность: quick ratio 1.15 и current ratio 1.53 ниже отраслевых ориентиров и заметно просели относительно более комфортных уровней в течение года. Долговая нагрузка повышенная: debt/equity 0.77 выше медианы и вырос по сравнению с предыдущими кварталами, а long-term debt остаётся значительным. Сильная сторона — масштаб и стабильность денежных потоков: выручка, EBITDA, операционная и чистая прибыль остаются высокими, а маржа прибыли держится на хорошем уровне. Динамика выручки и прибыли в целом положительная, но без ускорения, которое могло бы оправдать очень высокий базовый прогноз. Дивидендная доходность практически отсутствует, поэтому инвестор получает ставку прежде всего на рост бизнеса и качество исполнения, а не на текущий денежный поток от дивидендов. В сумме фундаментал поддерживает премиальную оценку, но текущие мультипликаторы и баланс рисков говорят о необходимости умеренно более консервативного взгляда на целевую цену.

Thermo Fisher Scientific Inc

Сильный индекс, значительно упал. Быки в растерянности.

Strong index, significantly down. The bulls are confused.

Слабый индекс, незначительно упал. Рынок не поддерживает быков.

Weak index, slightly down. The market does not support the bulls.

Средний индекс, незначительно вырос. Отток средств из лонгов снизился, но остается значительным.

Medium index, slightly up. The outflow of funds from longs has decreased, but remains significant.

Сильная прибыльность и стабильная выручка поддерживают TMO, но высокая оценка, слабая ликвидность и повышенный долг ограничивают потенциал роста.

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $415.7 million dollar inflow -- that's a 1.1% increase week over week in outstanding units (from 252,115,324 to 254,815,324). Among the largest underlying components of XLV, in trading today Amgen Inc (Symbol: AMGN) is down about 0.3%, Thermo Fisher Scientific Inc (Symbol: TMO) is off about 0.5%, and Gilead Sciences Inc (Symbol: GILD) is lower by about 1.1%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average:
Looking at the chart above, XLV's low point in its 52 week range is $127.96 per share, with $160.59 as the 52 week high point — that compares with a last trade of $153.52. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Further XLV Research:
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

XLV, AMGN, TMO, GILD: ETF Inflow Alert

ICON plc ICLR has put valuation back in focus after a -16.2% year-to-date drop, even as the stock is up 9.9% over the past 12 months. The move looks softer than the broader tape, with the S&P 500 up 10.2% year to date and up 29.3% over the past year.
Against its benchmarks, the setup is mixed. The Zacks sub-industry and Zacks Medical sector are down 11.2% and 7.5% year to date, and down 3.2% and up 0.8% over the past year, respectively. That dispersion matters because it shapes whether the stock’s multiple is truly “cheap” or simply reflecting a shifting earnings backdrop.
ICON’s Forward Multiple vs Benchmarks
On the surface, the valuation case is straightforward. ICON trades at 14.7X forward 12-month earnings, below 15.0X for the Zacks sub-industry, 19.5X for the Zacks Medical sector and 22.0X for the S&P 500.
That discount is not subtle, and it is also below the company’s own five-year median multiple of 18.3X (with a five-year range of 6.3X to 33.6X). The market is already paying less for each dollar of expected earnings than it does for peers and the broader index. The key question is whether that gap compensates investors for near-term uncertainty.
Image Source: Zacks Investment Research
ICLR’s Price Target Logic and What It Assumes
The price target is explicitly multiple-driven. ICON’s $145 target is based on 12.2X forward 12-month earnings, which sits close to the current trading multiple. That construction frames the call as one where upside is not dependent on a re-rating. It is largely about whether earnings execution stabilizes while the multiple remains restrained.
The multiple choice also matches a view that the stock is likely to lag the market over the next 6 to 12 months. With a cautious outlook already embedded, investors are left weighing whether incremental proof points can lift confidence enough to expand the valuation, or whether the reset keeps a lid on what the market is willing to pay.
ICON’s 2026 Guidance Creates a Multiple Trap Risk
A lower forward multiple can look attractive, but the “E” in the ratio is where the tension sits for ICON. Management guided to 2026 revenue of $7.85-$8.15 billion and adjusted earnings per share of $10.00-$11.00. That implies a down year versus 2025 revenue of $8.25 billion and adjusted earnings per share of $12.53.
The guidance is tied to prior-year cancellations and a weaker bookings environment that persisted from 2024 through the first three quarters of 2025, with elevated cancellation activity weighing on 2026 conversion. Pass-through revenue is expected to remain broadly in line with 2025 levels, which implies a steeper decline in direct fee revenue and can limit growth visibility even as commercial indicators improve. In that context, a “cheap” multiple can become a trap if estimates keep resetting lower.
ICON’s Margin Path Is the Real Catalyst or Warning
Margins are where the next leg likely gets decided. Fourth-quarter 2025 results showed how quickly profitability can swing when mix and estimates move. Pass-through revenue exceeded expectations by more than $150 million, and a portfolio review drove cost-to-complete and realizable value adjustments that management said reduced quarterly earnings by more than $50 million. Adjusted EBITDA margin fell to 15.5%, and adjusted earnings per share dropped to $2.52 from $3.86 a year ago.
Management expects first-quarter 2026 results to start near that fourth-quarter run rate and to improve through 2026, but the weaker starting point increases sensitivity to mix, pass-through timing and operational efficiency initiatives. Management also flagged that 2026 margins will be shaped by mix and sustained pass-through levels, with automation and technology deployment targeted to support margin progression. Execution risk is high because even small deviations in portfolio assumptions can flow directly into profitability.
Based on short-term price targets offered by 14 analysts, the average price target of $151.57 represents an decrease of 0.8% from the last closing price.
Image Source: Zacks Investment Research
ICLR’s Decision Lens for Investors
For investors with a transaction mindset, the valuation discount is real, but it is not the only variable. The stock carries Zacks Rank #5 (Strong Sell). That rating keeps the burden of proof on the company to demonstrate that remediation is fully embedded and that operational performance can stabilize through the reset year.
The “cheap enough” question hinges on credibility around remediation, evidence that bookings and cancellations are stabilizing, and signs that margins can climb from the lower early-2026 starting level. In the peer set, IQVIA Holdings Inc. IQV and Thermo Fisher Scientific Inc. TMO both carry Zacks Rank #3 (Hold), underscoring how differently the market is treating near-term visibility and execution risk across the group.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ICON PLC (ICLR) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

ICON Stock Valuation vs Peers: Is ICLR Cheap Enough?

ICON plc ICLR is moving through a credibility and earnings reset that is now as much about controls as it is about demand. The company has laid out the scope of its accounting findings, flagged material weaknesses, and set expectations for a down year in 2026.
With profitability showing heightened sensitivity to mix and estimates, investors are likely to focus on execution and consistency. ICON currently carries a Zacks Rank #5 (Strong Sell).
ICLR’s Investigation Findings and Restatement Scope
ICON’s Audit Committee review concluded that improper adjustments were made to clinical trial services revenue from third-quarter 2023 through fourth-quarter 2024. The issue primarily impacted the timing of revenue recognition, rather than the underlying business activity.
The company disclosed the findings resulted in an overstatement of full-year revenue of $65 million in 2023 and $93 million in 2024. Beyond the revenue timing, the review also cited errors tied to cost-to-complete estimates, realizable value assessments, and certain manual adjustments that extended into 2025.
In the past year, ICLR shares have surged 9.9% against the industry’s 3.2% decline.
Image Source: Zacks Investment Research
For investors, the timing element matters because it goes to the reliability of reported trend lines. When revenue is shifted across periods, it can distort growth comparisons, backlog conversion assumptions, and margin expectations that are built from quarterly patterns.
ICON’s Control Weaknesses and Remediation Timeline Risk
Alongside the investigation findings, ICON identified material weaknesses in internal controls over financial reporting. The company cited gaps in both entity-level controls and controls over revenues and related accounts, which raises the bar for proving that the process is now repeatable and durable.
Management is implementing a remediation plan that includes organizational changes, revised policies and procedures, additional training, and tighter controls over manual adjustments. The direction is clear: reduce discretion, improve oversight, and standardize how revenue-related judgments are made and reviewed.
The confidence overhang is the timeline. Management has signaled that fully embedding remediation across 2026 remains a key risk for investor confidence, which can keep valuation and sentiment capped even if operating metrics begin to stabilize.
ICLR’s Q4 Profitability Drop Shows Estimate Sensitivity
Fourth-quarter 2025 results highlighted how quickly profitability can swing when mix and estimates move together. Adjusted earnings per share fell to $2.52 from $3.86 in the prior-year quarter, while adjusted EBITDA margin declined to 15.5%.
Two drivers stood out. First, pass-through revenue exceeded expectations by more than $150 million, pressuring margin because these revenues typically carry lower profitability than direct fees. Second, a comprehensive review of the full-service portfolio drove cost-to-complete and realizable value adjustments that management said reduced quarterly earnings by more than $50 million.
The takeaway is that the model’s near-term earnings power is highly sensitive to project mix and estimation discipline. Until that volatility fades, quarter-to-quarter results may be harder for investors to underwrite with confidence.
The Zacks Consensus Estimate for ICLR’s 2026 sales and EPS implies a year-over-year decrease of 2% and 5.3%, respectively. The bottom-line estimates have moved south in the past 30 days.
Image Source: Zacks Investment Research
ICON’s 2026 Guide Frames a Down Year and Reset
ICON’s guidance frames 2026 as a reset year. Management guided to revenue of $7.85-$8.15 billion and adjusted earnings per share of $10.00-$11.00, compared with full-year 2025 adjusted earnings per share of $12.53.
Management tied the outlook to weaker bookings that persisted from 2024 into the first three quarters of 2025 and to elevated cancellations in recent quarters, which are expected to weigh on conversion in 2026. The company also indicated that part of the projected revenue decline reflects the Symphony Health divestiture, with the rest tied to organic weakness.
Mix and pricing are also key. With pass-through revenue expected to remain broadly in line with 2025 levels, the guidance implies a steeper decline in direct fee revenue. That dynamic can constrain margins, particularly given earlier pricing limitations that management cited as part of the setup.
For context, investors often compare ICON with other large clinical research and services players such as IQVIA Holdings IQV and Thermo Fisher Scientific TMO. If sector peers show steadier conversion or cleaner margin trajectories, ICON’s reset period may look more demanding by comparison.
ICON’s What to Watch Into 2026 and Early 2027
Management expects first-quarter 2026 results to start near the weaker fourth-quarter run rate. That sets a low starting point and increases the importance of sequential execution as the year progresses.
ICON expects margin improvement through 2026, but sensitivity remains elevated. Investors should watch project mix, pass-through revenue timing, and whether operational efficiency initiatives translate into measurable margin progression.
The other key marker is whether remediation efforts become fully embedded across 2026. A cleaner control environment, paired with steadier conversion, would likely be the foundation for rebuilding confidence into early 2027.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ICON PLC (ICLR) : Free Stock Analysis Report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

ICLR Earnings Reset: What the Accounting Probe Changed

A month has gone by since the last earnings report for TransMedics (TMDX). Shares have lost about 4.4% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is TransMedics due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its latest earnings report in order to get a better handle on the important drivers.
TransMedics Q1 Earnings & Revenues Miss Estimates
TransMedics delivered earnings per share of 30 cents in the first quarter of 2026, down 59.5% year over year. The figure missed the Zacks Consensus Estimate by 51.6%.
TMDX’s Q1 Revenues in Detail
TransMedics registered revenues of $173.9 million in the first quarter, up 21% year over year. The figure fell short of the Zacks Consensus Estimate by 1%.
Per management, the year-over-year rise was driven by the increased utilization of the Organ Care System ("OCS"), primarily in Liver and Heart through the National OCS Program ("NOP"), as well as additional revenues generated by TransMedics logistics services.
During the reported quarter, TMDX was able to cover 82% of its NOP missions requiring air transport compared with 78% in the first quarter of 2025.
TransMedics’ Segment Details
TMDX derives revenues via two sources: Net product revenues and Service revenues.
In the first quarter of 2026, Net product revenues totaled $108 million, up 22% year over year. Growth was driven by continued strong liver performance and modest growth in the heart.
Service revenues totaled $66 million, up 19% year over year, driven primarily by logistics revenues, supported by increased utilization of the TransMedics aviation fleet.
Transplant Logistics’ services revenues for first-quarter 2026 were $32 million, up 22% year over year. This resulted from the continued expansion and strong utilization of TransMedics’ aviation fleet.
TMDX’s Margin Trend
In the quarter under review, TransMedics’ gross profit increased 14.7% year over year to $101.2 million. The gross margin contracted 331 basis points (bps) to 58%.
Selling, general and administrative expenses rose 44.4% year over year to $62.9 million. Research, development and clinical trials expenses surged 45% year over year to $24.9 million. Total operating expenses of $87.9 million increased 44.5% year over year.
Adjusted operating profit totaled $18.1 million, reflecting a downtick of 39.2% from the prior-year quarter. The adjusted operating margin in the first quarter contracted 1030 bps to 10.4%.
TransMedics’ Financial Position
TransMedics exited first-quarter 2026 with cash of $461.7 million compared with $488.4 million at the end of 2025. Total long-term debt at the end of first-quarter 2026 was $44.5 million compared with $49.6 million at the end of 2025.
Net cash provided by operating activities at the end of first-quarter 2026 was $24.5 million, against net cash used in operating activities of $2.9 million a year ago.
TMDX’s 2026 Guidance
TransMedics reiterated its revenue outlook for 2026.
For 2026, the company expects revenues in the range of $727-$757 million, reflecting growth of 20-25% from the 2025 level. The Zacks Consensus Estimate is pegged at $739.7 million.
How Have Estimates Been Moving Since Then?
Since the earnings release, investors have witnessed a downward trend in fresh estimates.
The consensus estimate has shifted -29.46% due to these changes.
VGM Scores
Currently, TransMedics has a nice Growth Score of B, though it is lagging a lot on the Momentum Score front with an F. However, the stock has a grade of C on the value side, putting it in the middle 20% for value investors.
Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Interestingly, TransMedics has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry Player
TransMedics is part of the Zacks Medical - Instruments industry. Over the past month, Thermo Fisher Scientific (TMO), a stock from the same industry, has gained 0.2%. The company reported its results for the quarter ended March 2026 more than a month ago.
Thermo Fisher reported revenues of $11.01 billion in the last reported quarter, representing a year-over-year change of +6.2%. EPS of $5.44 for the same period compares with $5.15 a year ago.
For the current quarter, Thermo Fisher is expected to post earnings of $5.75 per share, indicating a change of +7.3% from the year-ago quarter. The Zacks Consensus Estimate remained unchanged over the last 30 days.
The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Thermo Fisher. Also, the stock has a VGM Score of D.
Beyond Nvidia: AI's Second Wave Is Here
The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. AI’s second wave is moving from infrastructure to implementation and these companies are at the forefront of this transition, positioned to become what Amazon and Google were to the internet era.
See Stocks Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

TransMedics (TMDX) Down 4.4% Since Last Earnings Report: Can It Rebound?

QuidelOrtho QDEL is being reminded that respiratory testing can still significantly influence results even after the post-pandemic reset. A milder and shorter U.S. respiratory season weighed heavily on first-quarter 2026 performance, with management attributing the weakness to lower demand rather than market-share losses.
The distinction is important because respiratory testing remains a meaningful profit driver for the company. While testing protocols remained unchanged and management indicated that market share was stable, influenza-like illness visits declined roughly 30% year over year during the quarter. The weaker patient volumes translated directly into lower testing demand across retail and healthcare settings.
As a result, respiratory revenue fell 43.3% year over year to $67.9 million. The decline highlights an important reality for QuidelOrtho: even when competitive positioning remains intact, a shrinking testing market can materially impact financial performance. QDEL currently carries a Zacks Rank #5 (Strong Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Image Source: Zacks Investment Research
The respiratory shortfall weighed on overall results. First-quarter revenue declined 10.5% year over year to $619.8 million, while the company reported an adjusted loss of 4 cents per share against adjusted earnings of 74 cents per share in the prior-year period. Non-respiratory revenue declined a more modest 3.7% to $551.9 million, helping offset some of the weakness but not enough to fully counter the steep drop in respiratory sales.
Profitability also came under pressure. Adjusted gross margin contracted 630 basis points year over year to 43.8%, reflecting a less favorable product mix and a lower contribution from respiratory testing. The margin impact underscores how sensitive QuidelOrtho's earnings profile remains to fluctuations in respiratory demand.
The softer season also affected working capital. Management noted that lower-than-expected respiratory volumes resulted in elevated inventory levels as production plans exceeded realized demand. This inventory build contributed to weaker cash generation, with operating activities using $33 million during the quarter compared with providing $65.6 million in the year-ago period.
The link between respiratory demand, profitability and cash flow remains straightforward. Lower testing volumes reduce operating leverage, pressure margins through unfavorable mix shifts and can leave inventory levels above expectations. While management continues to pursue productivity and procurement initiatives, respiratory seasonality is likely to remain a key driver of near-term performance.
Compared with more diversified diagnostics peers such as Abbott Laboratories ABT and Thermo Fisher Scientific TMO, QuidelOrtho remains more exposed to fluctuations in seasonal respiratory testing demand. The broader business mix at these companies helps cushion the impact of weakness in any single testing category.
For investors, the first-quarter results reinforce that stable market share alone cannot offset the effects of a shrinking end market. Until respiratory testing demand normalizes, QuidelOrtho is likely to face periodic revenue volatility, margin pressure and working-capital challenges tied to seasonal demand trends.
QDEL’s Sales & EPS Picture
In 2026, QDEL is expected to experience a 1.8% decline in revenues. On the profitability front, earnings per share are expected to decline 5.2% year over year.
Image Source: Zacks Investment Research
QDEL’s Valuation Picture
QDEL currently trades at a price-to-book ratio of 0.49X, well below its median level of 0.70X over the past year and significantly lower than the industry’s 2.04X.
Image Source: Zacks Investment Research
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

QuidelOrtho's Respiratory Exposure Remains a Key Near-Term Risk

For Immediate Release
Chicago, IL – June 2, 2026 – Zacks.com announces the list of stocks and featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Microsoft Corp. MSFT, Dell Technologies Inc. DELL, Thermo Fisher Scientific Inc. TMO, Village Super Market, Inc. VLGEA and Comstock Holding Companies, Inc. CHCI.
Here are highlights from Tuesday’s Analyst Blog:
Top Analyst Reports for Microsoft, Dell and Thermo Fisher
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corp. (MSFT), Dell Technologies Inc., and Thermo Fisher Scientific Inc., as well as two micro-cap stocks, Village Super Market, Inc., and Comstock Holding Companies, Inc. The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.
These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Ahead of Wall Street
The daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens, attempting to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.
You can read today's AWS here >>> Pre-Markets Turn South on News from Middle East
Today's Featured Research Reports
Microsoft’s shares have outperformed the Zacks Computer - Software industry over the past year (+0.5% vs. -4.3%). The company capitalizes on AI business momentum and Copilot adoption alongside accelerating Azure cloud infrastructure expansion. Strong Microsoft 365 Commercial cloud demand has been propelling Productivity and Business Processes revenue growth.
ARPU is increasing through E5 and M365 Copilot uptake across key segments. Strategic execution through expanding scale and enterprise customer growth is driving non-AI services. Azure growth guidance projects Q4 growth of 39-40% at cc, suggesting demand saturation, with customer demand exceeding available capacity.
Customer concentration risk remains tied to large OpenAI-related Azure commitments. Microsoft confronts intense competition from AWS and Google Cloud and escalating regulatory scrutiny. Capacity constraints persisting through fiscal year-end limit revenue potential despite unprecedented spending.
(You can read the full research report on Microsoft here >>>)
Shares of Dell have outperformed the Zacks Computer - Micro Computers industry over the past year (+324.3% vs. +60.7%). The company is seeing demand for AI servers stay ahead of supply as customers accelerate deployments and lock in capacity. In first quarter fiscal 2027, the company booked $24.4 billion of AI orders, delivered $16.1 billion of AI server revenue, and ended with a $51.3 billion AI backlog.
Management raised fiscal 2027 revenue guidance to $165-$169 billion and lifted expected AI server revenue to about $60 billion. ISG profitability improved year over year, and traditional servers, storage and commercial PCs are expanding, supporting cash flow and continued buybacks and dividends. DELL’s core leverage ratio was 1.2x exiting the quarter, but the balance sheet remains geared.
However, unfavorable AI mix and memory constraints continues to keep gross margin under pressure. Competitive pricing, and unfavorable forex are other headwinds.
(You can read the full research report on Dell here >>>)
Thermo Fisher’s shares have outperformed the Zacks Medical - Instruments industry over the past year (+23.9% vs. -3.5%). The company is building out its capabilities through the ongoing execution of its proven growth strategy. The year started on a solid note, with several high-impact innovations launched that support the company’s strong positioning in the industry.
Performance across the pharma and biotech end market continues to be driven by the bioproduction business, and the research and safety market channel. The addition of Solventum’s filtration and separation business extends its bioproduction capabilities.
The company’s new acquisition, Clario, further strengthens its position as a partner to pharma and biotech customers and offers an attractive return profile for shareholders. However, ongoing macroeconomic pressures can weigh on Thermo Fisher’s performance. Currency woes and fierce competition add to the worry.
(You can read the full research report on Thermo Fisher here >>>)
Shares of Village Super Market have outperformed the Zacks Retail - Supermarkets industry over the past year (+24.2% vs. +15.4%). This microcap company with a market capitalization of $685.38 million has seen improving sales momentum, strengthening cash generation, and a visible reinvestment pipeline balanced against margin pressure and competitive risks.
Sales rose 5.7% year over year to $1.2 billion in the first half of fiscal 2026, with same-store sales increasing 3.7%, supported by digital growth, store remodels, and strength in fresh and pharmacy categories. Operating cash flow increased to $78.8 million, raising total cash to $161.2 million and improving liquidity metrics, which reduces reliance on external financing and supports capital projects.
However, gross margin declined 50 bps due to lower Wakefern-related income, promotional pressure, and sales mix shifts, highlighting earnings sensitivity in the low-margin grocery model. Despite these risks, the stock trades at significant valuation discounts to peers and the broader market.
(You can read the full research report on Village Super Market here >>>)
Comstock’s shares have outperformed the Zacks Building Products - Home Builders industry over the past year (+71.1% vs. +4.1%). This microcap company with market capitalization of $155.61 million, is transitioning toward a more predictable, fee-based business model, with approximately 90% of Q1 2026 revenues recurring or recognized over time. Revenues increased 38% year over year to $17.4 million, supported by growth across asset management, property management, and ParkX operations.
Expansion of the managed portfolio, including the acquisition of The Reed multifamily property, creates multiple revenue opportunities through management, operational, and ancillary service contracts. The newly established Data Center Platform provides exposure to long-term growth opportunities tied to AI and cloud infrastructure demand.
Key concerns include significant revenue concentration, with related-party customers accounting for 89% of Q1 revenues, negative operating cash flow despite reported profitability, and margin pressures. Current valuation levels remain below broader sector averages.
(You can read the full research report on Comstock here >>>)
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.
Today you can access their live picks without cost or obligation.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The Zacks Analyst Blog Highlights Microsoft, Dell, Thermo Fisher,Village Super Market and Comstock

Monday, June 1, 2026
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corp. (MSFT), Dell Technologies Inc. (DELL) and Thermo Fisher Scientific Inc. (TMO), as well as two micro-cap stocks Village Super Market, Inc. (VLGEA) and Comstock Holding Companies, Inc. (CHCI). The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.
These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Ahead of Wall Street
The daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens, attempting to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.
You can read today's AWS here >>> Pre-Markets Turn South on News from Middle East
Today's Featured Research Reports
Microsoft’s shares have outperformed the Zacks Computer - Software industry over the past year (+0.5% vs. -4.3%). The company capitalizes on AI business momentum and Copilot adoption alongside accelerating Azure cloud infrastructure expansion. Strong Microsoft 365 Commercial cloud demand has been propelling Productivity and Business Processes revenue growth.
ARPU is increasing through E5 and M365 Copilot uptake across key segments. Strategic execution through expanding scale and enterprise customer growth is driving non-AI services. Azure growth guidance projects Q4 growth of 39-40% at cc, suggesting demand saturation, with customer demand exceeding available capacity.
Customer concentration risk remains tied to large OpenAI-related Azure commitments. Microsoft confronts intense competition from AWS and Google Cloud and escalating regulatory scrutiny. Capacity constraints persisting through fiscal year-end limit revenue potential despite unprecedented spending.
(You can read the full research report on Microsoft here >>>)
Shares of Dell have outperformed the Zacks Computer - Micro Computers industry over the past year (+324.3% vs. +60.7%). The company is seeing demand for AI servers stay ahead of supply as customers accelerate deployments and lock in capacity. In first quarter fiscal 2027, the company booked $24.4 billion of AI orders, delivered $16.1 billion of AI server revenue, and ended with a $51.3 billion AI backlog.
Management raised fiscal 2027 revenue guidance to $165-$169 billion and lifted expected AI server revenue to about $60 billion. ISG profitability improved year over year, and traditional servers, storage and commercial PCs are expanding, supporting cash flow and continued buybacks and dividends. DELL’s core leverage ratio was 1.2x exiting the quarter, but the balance sheet remains geared.
However, unfavorable AI mix and memory constraints continues to keep gross margin under pressure. Competitive pricing, and unfavorable forex are other headwinds.
(You can read the full research report on Dell here >>>)
Thermo Fisher’s shares have outperformed the Zacks Medical - Instruments industry over the past year (+23.9% vs. -3.5%). The company is building out its capabilities through the ongoing execution of its proven growth strategy. The year started on a solid note, with several high-impact innovations launched that support the company’s strong positioning in the industry.
Performance across the pharma and biotech end market continues to be driven by the bioproduction business, and the research and safety market channel. The addition of Solventum’s filtration and separation business extends its bioproduction capabilities.
The company’s new acquisition, Clario, further strengthens its position as a partner to pharma and biotech customers and offers an attractive return profile for shareholders. However, ongoing macroeconomic pressures can weigh on Thermo Fisher’s performance. Currency woes and fierce competition add to the worry.
(You can read the full research report on Thermo Fisher here >>>)
Shares of Village Super Market have outperformed the Zacks Retail - Supermarkets industry over the past year (+24.2% vs. +15.4%). This microcap company with a market capitalization of $685.38 million has seen improving sales momentum, strengthening cash generation, and a visible reinvestment pipeline balanced against margin pressure and competitive risks.
Sales rose 5.7% year over year to $1.2 billion in the first half of fiscal 2026, with same-store sales increasing 3.7%, supported by digital growth, store remodels, and strength in fresh and pharmacy categories. Operating cash flow increased to $78.8 million, raising total cash to $161.2 million and improving liquidity metrics, which reduces reliance on external financing and supports capital projects.
However, gross margin declined 50 bps due to lower Wakefern-related income, promotional pressure, and sales mix shifts, highlighting earnings sensitivity in the low-margin grocery model. Despite these risks, the stock trades at significant valuation discounts to peers and the broader market.
(You can read the full research report on Village Super Market here >>>)
Comstock’s shares have outperformed the Zacks Building Products - Home Builders industry over the past year (+71.1% vs. +4.1%). This microcap company with market capitalization of $155.61 million, is transitioning toward a more predictable, fee-based business model, with approximately 90% of Q1 2026 revenues recurring or recognized over time. Revenues increased 38% year over year to $17.4 million, supported by growth across asset management, property management, and ParkX operations.
Expansion of the managed portfolio, including the acquisition of The Reed multifamily property, creates multiple revenue opportunities through management, operational, and ancillary service contracts. The newly established Data Center Platform provides exposure to long-term growth opportunities tied to AI and cloud infrastructure demand.
Key concerns include significant revenue concentration, with related-party customers accounting for 89% of Q1 revenues, negative operating cash flow despite reported profitability, and margin pressures. Current valuation levels remain below broader sector averages.
(You can read the full research report on Comstock here >>>)
Other noteworthy reports we are featuring today include L3Harris Technologies, Inc. (LHX), MasTec, Inc. (MTZ) and Ingersoll Rand Inc. (IR).
Mark Vickery
Senior Editor
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>
Today's Must Read
Featured Reports
L3Harris (LHX) Gains From Acquisitions Amid Labor Shortage
Per the Zacks analyst, L3Harris Technologies is likely to benefit from increasing strategic acquisitions. Yet labor shortage result in delays and likely impact operating results.
Higher Order Rate to Aid Ingersoll Rand (IR) Amid High Costs
Per the Zacks analyst, higher orders across Ingersoll Rand's product portfolio of industrial vacuums, blowers and compressors will lend momentum to it. The company's high costs remain a woe.
Broadridge (BR) Gains From Recurring Revenue Model, Amid High Rivalry
Per the Zacks analyst, a robust business model, backed by higher recurring fee revenues, boosts Broadridge's top line. High competition from other players is an overhang.
AI-Led Customer Relevance Aids CDW Amid Elevated Debt Load
Per the Zacks analyst, CDW's customer-first approach continues to support growth as organizations move from AI experimentation toward production deployments. However, substantial leverage is a woe.
Extensive Fuel Distribution Operations to Benefit Sunoco LP (SUN)
Per the Zacks analyst, Sunoco gains from 9,000+ distribution facilities under long-term agreements. However, high leverage, acquisition risks and market volatility may pressure Sunoco's growth.
Xenon (XENE) Lead Candidate Progressing Well, Dependency a Woe
Per the Zacks Analyst, Xenon's clinical studies on azetukalner for treating epilepsy and other neuro disorders are progressing well. However, the lack of other candidates in its pipeline is a woe.
Skyward Specialty (SKWD) to Grow on Diversified Portfolio, Costs High
Per the Zacks analyst, Skyward Specialty's diversified portfolio will ensure its top-line growth. However, growing expenses are eating into its profit growth.
New Upgrades
MasTec (MTZ) Gains on Record Backlog and Data Center Demand Growth
Per the Zacks analyst, record backlog, favorable infrastructure spending trends and expanding opportunities in data centers and power markets continue to support MasTec's long-term growth prospects.
Digital & Store Initiatives to Aid Dillard's (DDS) Growth Story
Per the Zacks analyst, Dillard's is expected to gain from its focus on increasing productivity at existing stores, developing a leading omni-channel platform and enhancing domestic operations.
Credit, Funding, Multiproduct Mix & Partner Strength Aid Pagaya (PGY)
Per the Zacks analyst, secular growth in embedded credit, rising efficiency, diversified funding, growing partner base and multiproduct adoption will aid Pagaya's scalable and profitable expansion.
New Downgrades
Rising Expenses Likely to Hurt Elastic's (ESTC) Profitability
Per the Zacks analyst, aggressive investments to support AI and the go-to-market roadmap is likely to hurt Elastic's profitability in the near term.
Housing Market Softness & Inflationary Pressures Hurt Mohawk (MHK)
Per the Zacks analyst, Mohawk is being hurt by housing market softness, lower consumer confidence and weak demand trends. Also, inflationary pressures and tariff-related uncertainties remain concerns.
Elevated Expenses, Weak Asset Quality Hurt ICICI Bank's (IBN) Profits
Per the Zacks analyst, rising expenses, mainly due to ICICI Bank's initiatives to digitize banking operations, are expected to hamper bottom-line growth. Weak credit quality is another concern.
Radical New Technology Could Hand Investors Huge Gains
Quantum Computing is the next technological revolution, and it could be even more advanced than AI.
While some believed the technology was years away, it is already present and moving fast. Large hyperscalers, such as Microsoft, Google, Amazon, Oracle, and even Meta and Tesla, are scrambling to integrate quantum computing into their infrastructure.
Senior Stock Strategist Kevin Cook reveals 7 carefully selected stocks poised to dominate the quantum computing landscape in his report, Beyond AI: The Quantum Leap in Computing Power.
Kevin was among the early experts who recognized NVIDIA's enormous potential back in 2016. Now, he has keyed in on what could be "the next big thing" in quantum computing supremacy. Today, you have a rare chance to position your portfolio at the forefront of this opportunity.
See Top Quantum Stocks Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Top Analyst Reports for Microsoft, Dell & Thermo Fisher

Thermo Fisher Scientific TMO shares ended the last trading session 6.8% higher at $487.22. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 2.2% loss over the past four weeks.
Thermo Fisher scored a strong price increase on investors’ optimism surrounding the company’s solid first quarter of 2026 performance. The company posted adjusted earnings per share (EPS) of $5.44 while revenues came in at $11.01 billion in the first quarter.
This maker of scientific instrument and laboratory supplies is expected to post quarterly earnings of $5.75 per share in its upcoming report, which represents a year-over-year change of +7.3%. Revenues are expected to be $11.61 billion, up 7% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Thermo Fisher, the consensus EPS estimate for the quarter has been revised 0.5% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on TMO going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Thermo Fisher is a member of the Zacks Medical - Instruments industry. One other stock in the same industry, AngioDynamics ANGO, finished the last trading session 0.4% lower at $11.79. ANGO has returned 11.1% over the past month.
AngioDynamics' consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.11. Compared to the company's year-ago EPS, this represents a change of -266.7%. AngioDynamics currently boasts a Zacks Rank of #2 (Buy).
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Thermo Fisher (TMO) Surges 6.8%: Is This an Indication of Further Gains?

QIAGEN N.V. QGEN is sending investors a mixed near-term message after first-quarter earnings miss and a reset to its 2026 growth outlook. The stock carries a Zacks Rank #3 (Hold), and the Style Scores tilt defensive rather than directional.
With a VGM Score of D, QGEN screens as “balanced at best” today, especially with Value stronger than Growth and Momentum. The question is whether the company’s profitability and liquidity can steady the story while demand visibility stays choppy.
QIAGEN’s Q1 Print and What Drove the Miss
First-quarter 2026 results pointed to uneven demand and modest execution pressure. Adjusted earnings were $0.54 per share, down 2% year over year, and the result missed the consensus estimate by 1.2%. On a GAAP basis, earnings were $0.33 per share versus $0.41 a year ago.
Revenue was $492 million, up 2% year over year on a reported basis but down 1% at constant exchange rates. The top line also fell short of expectations, missing by 0.8%. Together, the numbers suggest demand did not cooperate evenly across end markets, and the company did not fully offset that with upside elsewhere during the quarter.
Based on short-term price targets from 10 analysts, the average price target for QIAGEN’s is $41.80, representing a potential 15.69% upside from the last closing price.
Image Source: Zacks Investment Research
QIAGEN’s Offsets: Profitability, Cash Flow, and Balance Sheet
Even with softer demand signals, QIAGEN delivered financial stabilizers that can matter in a reset year. The adjusted operating income margin was 27.4% in the first quarter, reflecting sustained profitability despite targeted investments and headwinds from tariffs and currency movements.
Cash generation also remained constructive. Free cash flow was $54 million in the quarter, supporting ongoing investment needs, including systems and infrastructure initiatives.
The balance sheet adds another layer of flexibility. QIAGEN ended the quarter with $646.3 million in cash and cash equivalents and no current debt. That liquidity can help the company keep funding targeted launches and workflow improvements, even as tariffs and foreign-exchange movements continue to pressure profitability.
QGEN’s Valuation Framing vs. Benchmarks
The stock’s decline provides important context for the current debate. QIAGEN shares are down 23.7% year to date and also down 23.7% over the past 12 months.
On valuation, QGEN trades at about 3.4 times forward 12-month sales. That is above the Zacks sub-industry and sector comparisons, but below the S&P 500 multiple shown in the same benchmark set.
Image Source: Zacks Investment Research
The $38 price target is framed through a multiple-based approach. It reflects 3.5 times forward 12-month sales, essentially signaling modest upside from recent levels while keeping expectations constrained by the slower growth outlook.
QIAGEN’s Decision Checklist From the Report’s Risks
For investors weighing a buy-versus-hold stance, the downside checklist is clear. QIAGEN remains sensitive to macro conditions and demand fluctuations, including reduced QuantiFERON immigration testing volumes, cautious spending from U.S. Life Sciences customers, and uneven original equipment manufacturer ordering patterns.
Foreign-exchange exposure is another swing factor, given that more than half of revenue is generated outside the United States. Tariffs also pressured profitability in the first quarter, and those costs can complicate margin forecasting while the company continues investing behind launches.
Execution timing in partnerships matters, too. Companion diagnostics programs can deliver multi-year opportunity, but revenue recognition depends on partner timelines and commercial success. QIAGEN reported $115 million in remaining performance obligations tied to companion diagnostic co-development contracts, with roughly half expected over the next 12 to 18 months.
Finally, competitive intensity can lengthen sales cycles when lab budgets tighten. That dynamic is not unique to QIAGEN. Illumina, Inc. ILMN is a major player in sequencing and array solutions used across genomics workflows, and spending cycles in that ecosystem can influence broader purchasing behavior. Thermo Fisher Scientific Inc. TMO also spans a wide range of life sciences research tools and consumables, underscoring how well-funded competitors can pressure pricing and decision timelines in cautious environments.
You can see the complete list of today’s Zacks Rank #1 (Strong Buy) stocks here.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
QIAGEN N.V. (QGEN) : Free Stock Analysis Report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Is QGEN Stock a Hold After the 2026 Outlook Cut and Q1 Miss?

QIAGEN QGEN has built a broad assay and biomarker portfolio that spans pre-analytical sample preparation and molecular diagnostics. That mix gives the company multiple shots on goal across clinical testing and life science workflows, even as spending patterns remain choppy.
The near-term setup is not uniform across end markets, but QIAGEN has shown it can protect profitability while continuing to fund targeted growth initiatives. Its Zacks Rank is #3 (Hold).
In the past year, QIAGEN’s shares have plunged roughly 23.7% against the industry’s growth of 18.7%.
Image Source: Zacks Investment Research
QGEN’s Portfolio Maps to Multiple Testing Growth Areas
QIAGEN positions itself as a provider of technologies for the separation, purification, and handling of DNA and RNA, with offerings that start at sample collection and preparation and extend into molecular diagnostics. The company has developed a portfolio of more than 500 proprietary consumable products, alongside automated solutions designed to support standardized workflows.
The strategic thread running through the portfolio is breadth of content, then expansion of that content over time. Management continues to emphasize expanding test menus and improving automation-driven workflows to keep platforms relevant as labs seek faster and more repeatable processes.
The company has also highlighted collaborations and commercial partnerships as a way to broaden distribution and accelerate assay development, particularly in companion diagnostics, where adopted content can translate into recurring consumables once testing becomes standardized.
QIAGEN’s Revenue Mix Shows Where Demand Is Concentrated
QIAGEN organizes its business into two main product buckets. Consumables and related revenues include consumable kits, bioinformatics solutions, royalties, co-development milestone payments, and services. Instruments and related services include instruments, services, and contracts.
Within that structure, the 2024 portfolio-area mix shows where demand is concentrated. Diagnostic Solutions represented 37.9% of sales, Sample Technologies 32.5%, PCR and Nucleic Acid Amplification 15.2%, Genomics and Next-Generation Sequencing 11.8%, and Other 2.7%.
Each portfolio area bundles distinct platforms and use cases. Diagnostic Solutions includes molecular testing platforms and consumables such as QuantiFERON, QIAstat-Dx, and NeuMoDx, alongside Precision Diagnostics. Sample Technologies covers consumables and instruments used in sample collection, stabilization, storage, purification, and quality control. PCR and Nucleic Acid Amplification includes research and applied polymerase chain reaction solutions and components, including QIAcuity. Genomics and Next-Generation Sequencing includes universal next-generation sequencing solutions and the full QIAGEN Digital Insights portfolio.
Estimates for QGEN Heading South
The Zacks Consensus Estimate for QIAGEN’s 2026 sales and EPS implies a year-over-year improvement of 4.1% and 2.5%, respectively. The bottom-line estimates have moved southward in the past 30 days.
Image Source: Zacks Investment Research
QIAGEN’s 2026–2027 Growth View and What It Implies
The Zacks model points to steady growth, even if the path is not linear. QIAGEN’s revenues are modeled to deliver a compound annual growth rate of 5.9% through 2027. Diagnostic Solutions is expected to grow 1.9% year over year in 2026, while Genomics and Next-Generation Sequencing is expected to grow 3.3% in 2026.
Operationally, the levers behind that outlook tie back to content and workflow. QIAGEN continues to invest in research and development to expand menus and improve throughput across core platforms, including new gastrointestinal panel clearances on the QIAstat-Dx Rise system and continued advancement of additional panels. Management has also pointed to sample preparation automation, including rollout activity for new Connect systems, and expects new launches to contribute about two percentage points of sales growth in the second half of 2026.
QGEN’s Key Watch Items Investors Should Track
A primary checkpoint is whether second-half 2026 delivers the expected acceleration to roughly 4% sales growth at constant exchange rates, supported by new product launches, sequential improvement in QuantiFERON, and contributions from Parse as it tracks toward a 2026 sales target of $40 million.
Investors should also monitor traction from new launches, including the new Connect systems, and whether added platform content keeps translating into higher utilization and consumables pull-through as labs consolidate testing onto scalable workflows.
Finally, the external environment matters. Management has cited tariffs and currency movements as headwinds that pressured profitability in the first quarter, and it reduced the full-year 2026 outlook to roughly 1% to 2% growth at constant exchange rates amid softer immigration testing volumes and continued caution from U.S. Life Sciences customers. Competitive intensity remains high across the company’s markets, with peers in the same industry group including Thermo Fisher Scientific TMO and Illumina ILMN, which can raise the bar for winning budgeted placements when customers stay cautious.
You can see the complete list of today’s Zacks Rank #1 (Strong Buy) stocks here.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
QIAGEN N.V. (QGEN) : Free Stock Analysis Report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Thermo Fisher Scientific Inc

Options Strategies